24 August 2015: Articles
Enucleation after Embolization of Liver Failure-Causing Giant Liver Hemangioma
Unusual clinical course, Unusual setting of medical care, Clinical situation which can not be reproduced for ethical reasons
Amit Sharma ABDEF , Matthew Kaspar BEF , Mohammad Siddiqui AE , Joohyun Kim ADEDOI: 10.12659/AJCR.893298
Am J Case Rep 2015; 16:563-567
Abstract
BACKGROUND: Hepatic hemangioma is a congenital tumor of the mesenchymal tissues of the liver. While typically benign, these tumors can occasionally grow to sufficient size to cause a number of symptoms, including pain, severe hepatic dysfunction, or, rarely, consumptive coagulopathy. In such instances, surgical treatment may be warranted.
CASE REPORT: We present a case of a symptomatic giant hepatic hemangioma in an elderly patient who presented with impending liver failure. She was successfully treated with a combination of surgical enucleation and liver resection after preoperative arterial embolization. We also provide a brief discussion of current treatment options for giant hepatic hemangiomas.
CONCLUSIONS: Early referral to experienced surgical centers before the onset of dire complications such as severe hepatic dysfunction and liver failure is recommended.
Keywords: Embolization, Therapeutic, Hemangioma - therapy, Hepatectomy, Liver Failure - therapy, Liver Neoplasms - therapy
Background
Hepatic hemangioma is a congenital tumor of the mesenchymal tissues of the liver. While typically benign, these tumors can occasionally grow to sufficient size to cause a number of symptoms, including pain, severe hepatic dysfunction, or, rarely, a consumptive coagulopathy (Kasabach-Merritt syndrome). In such instances, surgical treatment may be warranted. While multiple surgical techniques are described in the literature, enucleation is considered the safest and most effective approach. However, in the case of unusually large tumors, a multistage approach with a goal of pre-operative reduction in tumor size and vascularity with embolization may be advantageous. We present a case of a symptomatic giant hepatic hemangioma in an elderly patient that was successfully treated with combination of surgical enucleation and liver resection after preoperative arterial embolization. We also provide a brief discussion of current treatment options for giant hepatic hemangiomas.
Case Report
The patient was a 73-year-old African American woman with history of atrial fibrillation, hypothyroidism, diabetes, and hypertension. She had been diagnosed with a hepatic hemangioma approximately 35 years ago when she underwent an abdominal hysterectomy. She was managed conservatively and remained asymptomatic over the subsequent decades. She presented to our Emergency Department with recent onset of scleral icterus and increasing intensity of dull right upper-quadrant pain. This was accompanied by 1 week of light-colored stools and dark urine. Physical examination at presentation was significant for scleral icterus and a firm, distended, non-tender abdomen. The patient’s Karnofsky Performance Scale Index was 70%.
Laboratory evaluation revealed elevated liver enzymes (AST 840 U/L, ALT 515 U/L), hyperbilirubinemia (total bilirubin 14.5 md/dL, conjugated bilirubin 12.2 mg/dL), and coagulopathy (INR 3.1). Selected laboratory values are shown in Table 1. Computerized tomography of the abdomen showed multiple hypo-attenuating masses with peripheral nodular enhancement throughout the liver, suggestive of hemangiomas (Figure 1). The largest was located in the left hepatic lobe and measured 26.0×18.0×27.0 cm, with 2 other hemangiomas in the right lobe measuring 7.0×6.0 and 3.0×3.0 cm. The centers of these masses contained some hypodense areas, consistent with possible necrosis. There were no specific areas of biliary ductal dilation.
MRI of the abdomen (Figure 2) confirmed the presence of multiple masses in the liver with low T1 and high T2 attenuation, consistent with a diagnosis of massive hepatic hemangioma extending into the pelvis. Due to the patient’s advanced age, multiple medical co-morbidities, coagulopathy, and massive size of the tumor, hospice care at an outside hospital had been suggested. A transplant surgery opinion was sought by the consulting hepatologist at our center. A lengthy discussion was held with the patient and her family regarding risks and possible complications of surgical intervention. The patient decided against palliative care and consented to a high-risk surgical intervention.
The patient underwent hepatic angiography (Figure 3) prior to the planned resection. An uncomplicated partial embolization of the giant hemangioma via the left hepatic artery using 2 vials of 500–700 micron diameter embospheres was performed. Two days later she was taken to the operating room. Our liver transplant team, including an anesthesiologist and support staff, participated in this surgery. Provisions were made for backbench
A Cavitron Ultrasonic Surgical Aspirator (CUSA, Valleylab, USA) was used to divide a thin rim of segment IV, which was bridging across the anterior aspect of the tumor. This allowed access to an avascular plane between the compressed right lobe and the hemangioma. Monopolar coagulation and CUSA were then used to for enucleation of the hemangioma without any significant blood loss. The left hepatic vein was isolated. Ligation of the left hepatic artery, hepatic duct, and portal vein allowed mobilization of the posterior aspect of the hemangioma. The left hepatic vein and a thin rim of segments II and III were divided using a 2.5-mm endostapler (Autosuture™ GIA™ UNIVERSAL stapler, Norwalk, CT, USA). The specimen was sent for histopathological examination. The patient was extubated after 24 h, had an uneventful recovery, and was discharged home on post-operative day 7.
Estimated blood loss during surgery was approximately 900 mL. The patient received 1 unit of packed red cells, 1 dose of platelets, 2 doses of fresh frozen plasma, and 350 mL of autologous blood transfusion (Cell Saver® Elite®, Hemonetics, USA). The specimen weighed 5.5 kg, with approximate size of 30 cm by 20 cm (Figure 5). The histopathological examination confirmed a number of cavernous hemangiomas with infarction and degenerative changes, with a pattern of bilirubinostasis in the resected liver.
Liver enzymes and hyperbilirubinemia completely normalized by approximately 4 months after surgery (Table 1). A follow-up abdominal MRI performed 2 years after the surgery revealed small, stable hemangiomas (the largest measuring 6.0 cm in diameter) in the residual right lobe of the liver. The patient continues to do well and is asymptomatic nearly 3 years after her surgery.
Discussion
We present a case of a massive cavernous hepatic hemangioma causing compression and impending liver failure in a septuagenarian female that was successfully managed using a combination of enucleation and hepatic parenchymal resection after pre-operative embolization. This case highlights the fact that size of hemangioma and patient age should not automatically exclude them from consideration for surgical management. Timely referral of patients to a center with liver resection/transplantation capabilities could prove life-saving.
Hepatic hemangiomas are common, typically benign, lesions arising from the mesenchymal tissues of the liver [1]. Lesions are typically categorized by size, with the distinction of “giant” being reserved for those greater than 4 cm in diameter [1]. Histologically, they are characterized by cavernous, blood-filled sinuses, which are lined by vascular endothelium. They are typically considered to be congenital rather than a neoplastic processes, with poorly understood biology in regards to growth patterns and factors. Estimates of incidence in the general population range from 0.6 to 7% [2], and occur predominantly in the female population (3:1) [1]. There is a known association between lesion size and estrogen/progesterone levels, with lesion growth observed during pregnancy and in conjunction with the use of oral contraceptives and hormone replacement therapies [1].
Hepatic hemangiomas are typically managed expectantly because they carry a very low risk for complications such as progression to malignant disease or rupture [1]. The indications for operative management include pain/discomfort (22.5%), liver or abdominal organ dysfunction related to mass effect (32%, typically manifested by impaired hepatic function), suspicion of malignancy or inability to definitively diagnose a lesion as a hemangioma (20%), and a syndrome of consumptive coagulopathy known as Kasabach-Merritt syndrome (7.5%) [1].
First described in 1940 [2], Kasabach-Merritt syndrome is a thrombocytopenic purpura associated with an enlarging hemangioma. The typical presentation is profound thrombocytopenia (often less than 20×109 platelets/L), accompanied by consumptive coagulopathy and intravascular hemolysis reminiscent of disseminated intravascular coagulation (DIC). The proposed pathogenesis of this DIC is related to platelet activation and clumping when they come in contact with the abnormal endothelium of the tumor, leading to turbulent blood flow, shearing stresses, and hemolysis. Mainstays of therapy are primarily centered around obliteration of the tumor and its aberrant endothelium, which can be achieved by a number of techniques, including excision, embolization, radiotherapy, corticosteroids, or simply external compression with obliteration of the vascular space.
In our patient the main indication for surgery was evolving liver failure due to mass effect caused by the enormous hemangioma. Our choice of therapy and operative approach was based on the prior experience of a number of surgeons. Therapeutic options as described in the literature included ablation, enucleation, partial hepatic resection, and total hepatectomy with liver transplant [3–6]. While most case reports suggested enucleation (if technically feasible) as superior/non-inferior to hepatic resection [7–9], evidence supporting the role of preoperative angiography and ablation is less clear. A number of case reports [10,11] made attempts to use angiography as a primary therapy, with varying degrees of success. However, many reports [1,12] described the control of the hepatic pedicle, with periodic clamping, as a method to temporarily decrease tumor size in an effort to facilitate dissection and isolation of vessels supplying it.
In this case, we combined the techniques of embolization and periodic pedicle clamping to achieve the desired result – pre-operative angiographic left hepatic arterial embolization – to provide some degree of tumor size reduction (but not necrosis), and hepatic pedicle clamping for further reduction of tumor size or rapid in-flow control should the need arise. Most giant hemangiomas are most safely removed by enucleation when a good plane can be found between the tumor and liver parenchyma. With this ‘super’ giant cavernous hemangioma, we employed a combination technique of partly enucleating and partly resecting the liver parenchyma to achieve the desired outcomes with minimal blood product requirements. Additionally, a back table, as would be utilized during liver transplantation, was prepared in the event that uncontrollable hemorrhage mandated total hepatectomy with
Conclusions
Our experience with this patient serves to reinforce previously published reports suggesting the feasibility of safely resecting/enucleating giant hepatic hemangiomas. While technically challenging, these procedures can be accomplished successfully provided that sufficient support structure and facilities are available. We recommend that patients with giant, symptomatic hepatic cavernous hemangiomas are best served by early referral to experienced surgical centers before the onset of dire complications such as severe hepatic dysfunction or Kasabach-Merritt syndrome.
References:
1.. Giuliante F, Ardito F, Vellone M, Reappraisal of surgical indications and approach for liver hemangioma: single-center experience on 74 patients: Am J Surg, 2011; 201(6); 741-48, pmid: 20937504
2.. Hall GW, Kasabach-Merritt syndrome: pathogenesis and management: Br J Haematol, 2001; 112(4); 851-62, pmid: 11298580
3.. Concejero AM, Chen CL, Chen TY, Giant cavernous hemangioma of the liver with coagulopathy: adult Kasabach-Merritt syndrome: Surgery, 2009; 145(2); 245-47, pmid: 19167982
4.. Yildiz S, Kantarci M, Kizrak Y, Cadaveric liver transplantation for a giant mass: Gastroenterology, 2014; 146(1); e10-1, pmid: 24269562
5.. Vagefi PA, Klein I, Gelb B, Emergent orthotopic liver transplantation for hemorrhage from a giant cavernous hepatic hemangioma: case report and review: J Gastrointest Surg, 2011; 15(1); 209-14, pmid: 20549381
6.. Kumashiro Y, Kasahara M, Nomoto K, Living donor liver transplantation for giant hepatic hemangioma with Kasabach-Merritt syndrome with a posterior segment graft: Liver Transpl, 2002; 8(8); 721-24, pmid: 12149767
7.. Hochwald SN, Blumgart LH, Giant hepatic hemangioma with Kasabach-Merritt syndrome: is the appropriate treatment enucleation or liver transplantation?: HPB Surg, 2000; 11(6); 413-19, pmid: 10977121
8.. Zhong L, Men TY, Yang GD, Case report: living donor liver transplantation for giant hepatic hemangioma using a right lobe graft without the middle hepatic vein: World J Surg Oncol, 2014; 12(1); 83, pmid: 24708716
9.. Fu XH, Lai EC, Yao XP, Enucleation of liver hemangiomas: is there a difference in surgical outcomes for centrally or peripherally located lesions?: Am J Surg, 2009; 198(2); 184-87, pmid: 19324327
10.. Seo HI, Jo HJ, Sim MS, Kim S, Right trisegmentectomy with thoracoabdominal approach after transarterial embolization for giant hepatic hemangioma: World J Gastroenterol, 2009; 15(27); 3437, pmid: 19610149
11.. Vassiou K, Rountas H, Liakou P, Embolization of a giant hepatic hemangioma prior to urgent liver resection. Case report and review of the literature: Cardiovasc Intervent Radiol, 2007; 30(4); 800-2, pmid: 17508234
12.. Baer HU, Dennison AR, Mouton W, Enucleation of giant hemangiomas of the liver. Technical and pathologic aspects of a neglected procedure: Ann Surg, 1992; 216(6); 673-76, pmid: 1466621
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






